Valuation: EyePoint, Inc.

Market Cap 1.21B 1.06B 980M 917M 1.72B 114B 1.75B 11.78B 4.56B 56.14B 4.53B 4.43B 195B P/E 2026 *
-4.08x
P/E 2027 * -5.26x
Enterprise Value 913M 804M 741M 693M 1.3B 86.06B 1.32B 8.91B 3.45B 42.45B 3.43B 3.35B 148B EV / Sales 2026 *
535x
EV / Sales 2027 * 18.8x
Free-Float
96.32%
Yield 2026 *
-
Yield 2027 * -
1 day+0.14%
1 week+9.51%
Current month+6.04%
1 month+11.37%
3 months+14.38%
6 months-21.14%
Current year-21.18%
1 week 13.49
Extreme 13.49
14.88
1 month 11.3
Extreme 11.295
14.88
Current year 11.3
Extreme 11.295
18.87
1 year 8.96
Extreme 8.955
19.11
3 years 3.91
Extreme 3.91
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
42.5
Manager TitleAgeSince
Chief Executive Officer 68 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 68 10/07/2023
Director/Board Member 80 03/09/2024
Director/Board Member 58 15/07/2019
Date Insider Type Main position Quantity % Market Cap.
05-25Fiscal year

Chief Financial Officer

18,627 0.0222%
04-17Fiscal year

Chief Technology Officer

7,311 0.0088%
03-23Others

Chief Executive Officer

453,532 0.5478%
Change 5-day change 1-year change 3-year change Capi.($)
+0.14%+9.51%+56.86%+112.70% 1.21B
+0.92%+0.47%+43.59%+143.50% 996B
+0.80%+2.90%+58.35%+45.64% 580B
+0.06%+6.17%+26.59%+72.81% 415B
+4.24%-2.44%+22.01%+15.66% 326B
+0.35%+5.64%+31.26%+40.24% 280B
+1.11%+6.83%+37.12%+24.44% 284B
+1.23%+12.69%-27.48%-41.27% 210B
+1.27%+2.86%+26.65%+54.74% 190B
+0.09%-0.23%+16.75%+61.56% 155B
Average +0.23%+3.58%+29.17%+53.00% 343.79B
Weighted average by Cap. +0.06%+2.18%+33.97%+68.19%

Financials

2026 *2027 *
Net sales 1.71M 1.5M 1.39M 1.3M 2.43M 161M 2.47M 16.66M 6.45M 79.37M 6.41M 6.27M 276M 51.01M 44.91M 41.42M 38.74M 72.58M 4.81B 73.94M 498M 193M 2.37B 192M 187M 8.25B
Net income -311M -274M -253M -236M -443M -29.33B -451M -3.04B -1.18B -14.47B -1.17B -1.14B -50.34B -262M -231M -213M -199M -374M -24.74B -381M -2.56B -992M -12.21B -986M -964M -42.46B
Net Debt -294M -259M -239M -224M -419M -27.74B -427M -2.87B -1.11B -13.69B -1.11B -1.08B -47.62B -248M -219M -202M -189M -353M -23.4B -360M -2.42B -938M -11.54B -932M -912M -40.16B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
214
Date Price Change Volume
24/06/26 $14.40 +0.14% 895,082
23/06/26 $14.38 +4.73% 1,551,534
22/06/26 $13.73 +1.10% 842,461
18/06/26 $13.58 +3.27% 1,290,270
17/06/26 $13.15 +2.10% 1,180,462
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
14.40USD
Average target price
37.00USD
Spread / Average Target
+156.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock